Arkolith/Insider Trading/ZBIO/Form 4

Harwin Peter Evan

DirectorZenas BioPharma, Inc. (ZBIO) · full profile →Form 4 · filed Sep 16, 2024
Net Buying
Open-Market Buys
$5.1M
Open-Market Sells
$0
Net Open-Market Flow
$5.1M
Transactions
10
5 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 16, 2024Buy(P)300K$17.00$5.1M1.6M
Sep 16, 2024Conversion(C)710K——1.0M
Sep 16, 2024Conversion(C)253K——294K
Sep 16, 2024Conversion(C)301K——1.3M
Sep 16, 2024Conversion(C)41K——41K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 16, 2024Conversion(C)357K——0
Sep 16, 2024Conversion(C)2.2M——0
Sep 16, 2024Conversion(C)6.2M——0
Sep 16, 2024Conversion(C)2.6M——0
Sep 12, 2024Grant(A)37K—$037K

Transaction Codes

P
Open-market purchase
C
Conversion of a derivative
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-100330) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML